Apr. 29 2024
Source Page: Letters and medicine recalls sent to healthcare professionals in March 2024Found: genetic cause, due to structural hypothalamic pituitary abnormalities, due to central nervous system tumours
Mentions:
1: David Davis (Con - Haltemprice and Howden) Some time ago—a long time ago—my mother died of brain and lung cancer in considerable agony, pain and - Speech Link
2: Lia Nici (Con - Great Grimsby) Debbie had terminal cancer; tumours meant that she could not swallow or digest food any more. - Speech Link
Asked by: Alistair Strathern (Labour - Mid Bedfordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the availability of treatment for glioma on the NHS.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines, including medicines for glioma, to determine whether they represent a clinically and cost-effective use of resources. The NICE aims to publish guidance on new medicines as close as possible to licensing. Any medicine for glioma, recommended in draft NICE guidance, will be eligible for funding through the Cancer Drugs Fund from the point a positive draft guidance is published, in line with the standard arrangements for cancer medicines.
On 24 April 2024, the NICE published draft guidance recommending a new treatment for glioma in children and young people that will be available to eligible patients once supply of the treatment is available.
There are currently no licensed dendritic cell therapies for glioma. A number of dendritic cell therapies are in development for the treatment of glioma, and any new licensed and NICE recommended treatments would be funded by NHS England, in line with NICE’s recommendations.
Asked by: Alistair Strathern (Labour - Mid Bedfordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether NHS England plans to provide dendric cell therapy for glioma.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) evaluates all new licensed medicines, including medicines for glioma, to determine whether they represent a clinically and cost-effective use of resources. The NICE aims to publish guidance on new medicines as close as possible to licensing. Any medicine for glioma, recommended in draft NICE guidance, will be eligible for funding through the Cancer Drugs Fund from the point a positive draft guidance is published, in line with the standard arrangements for cancer medicines.
On 24 April 2024, the NICE published draft guidance recommending a new treatment for glioma in children and young people that will be available to eligible patients once supply of the treatment is available.
There are currently no licensed dendritic cell therapies for glioma. A number of dendritic cell therapies are in development for the treatment of glioma, and any new licensed and NICE recommended treatments would be funded by NHS England, in line with NICE’s recommendations.
Written Evidence Apr. 23 2024
Inquiry: City Region and Growth DealsFound: driving the development of imaging technology to understand and benefit diseases such as stroke, brain
Apr. 19 2024
Source Page: Scotland's Genomic Medicine Strategy 2024-2029Found: urgent priorities within genomic medicine in Scotland: 1) rare and inherited conditions, 2) solid tumours
Apr. 15 2024
Source Page: Brain Tumour Research Funding: FOI releaseFound: Brain Tumour Research Funding: FOI release
Apr. 15 2024
Source Page: Brain Tumour Research Funding: FOI releaseFound: Brain Tumour Research Funding: FOI release